Clinical Trials Browser

Phase 1 × INDUSTRY × HBI-8000 × Clear all

NCT02569489 2022-07-18

Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT02697552 2017-01-12

Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma

Phase 1 Completed

Lymphoma, Non-Hodgkin